IRF2 is an Essential Transcription Factor with Pathogenic and Prognostic Impact in Multiple Myeloma - PubMed
4 hours ago
- #Multiple Myeloma
- #IRF2
- #Transcription Factor
- IRF2 was identified as an essential transcription factor in multiple myeloma through CRISPR-Cas9 screening.
- IRF2 binds to chromatin independently and cooperatively with IRF1 and IRF4, affecting promoters and introns.
- Functionally, IRF2 supports myeloma cell survival by inhibiting necroptosis and promoting migration.
- IRF2-driven transcriptional changes appear early in disease precursors like MGUS and SMM.
- Higher IRF2 expression correlates with worse progression-free and overall survival in multiple myeloma patients.
- IRF2 represents a potential therapeutic target due to its pathogenic and prognostic impact.